Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420

Sherif S. Farag, Stephen L. George, Edward J. Lee, Maria Baer, Richard K. Dodge, Brian Becknell, Todd Fehniger, Lewis R. Silverman, Jeffrey Crawford, Clara D. Bloomfield, Richard A. Larson, Charles A. Schiffer, Michael A. Caligiuri

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Fingerprint

Dive into the research topics of 'Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420'. Together they form a unique fingerprint.

Medicine & Life Sciences